YK Bioventures Opportunities GP I, LLC's Form 4 filing
Cero Therapeutics Holdings, Inc.CERO · filed Nov 14, 2024
- Accession no.
- 0001415889-24-026908
- Filed
- Nov 14, 2024, 8:14 PM ET
- Trade date
- Oct 10, 2024
- Filing delay
- 35 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $325.0K. It was filed 35 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| YK Bioventures Opportunities GP I, LLCCIK 0002042634 | 10% Owner |
| YK Bioventures Opportunities Fund I, L.P.CIK 0002042636 | 10% Owner |
| Kossar Mitchell WilliamCIK 0002042691 | 10% Owner |
| Yeung Gary KahingCIK 0002042700 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 10, 2024 | Common Stock | SSaleDisposed | −3,250,000 | $0.10F1 | −$325,000 | 22,620,783 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.09 to $0.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.